导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -6.74% | 3544/4773 |
| 近一周 | -3.66% | 4431/5462 |
| 近一月 | -0.12% | 739/5421 |
| 近一季 | -1.36% | 979/5209 |
| 近半年 | -14.33% | 3906/4920 |
| 近一年 | -8.97% | 3291/4366 |
| 近两年 | 20.80% | 2632/2954 |
| 近三年 | 21.84% | 1407/2253 |
| 成立以来 | 34.64% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.98% 817/4961 |
-16.82% 4744/5312 |
- - |
- - |
| 2025 | 17.11% 2399/4813 |
1.04% 1713/3635 |
6.33% 460/4076 |
8.64% 3404/4524 |
0.32% 2058/4813 |
| 2024 | 12.02% 1280/3463 |
1.65% 867/2808 |
14.73% 8/3014 |
-1.83% 2960/3129 |
-2.17% 1984/3463 |
| 2023 | 3.11% 295/2656 |
3.67% 1149/2280 |
-2.04% 553/2385 |
-0.16% 405/2515 |
1.68% 77/2655 |
| 2022 | -11.77% 257/2207 |
-6.30% 213/1919 |
2.63% 1280/2016 |
-17.39% 1587/2113 |
11.06% 154/2208 |
| 2021 | 3.91% 598/1822 |
11.94% 19/1255 |
8.27% 640/1330 |
-8.10% 1100/1466 |
-6.71% 1545/1822 |
| 2020 | -0.86% 946/1250 |
-18.84% 1005/1028 |
7.31% 844/1067 |
6.47% 835/1164 |
6.91% 736/1184 |
| 2019 | 14.24% 698/1092 |
10.21% 720/739 |
-4.83% 433/788 |
-2.37% 697/850 |
11.56% 56/918 |
| 2018 | -13.14% 86/834 |
- - |
4.03% 12/631 |
-3.39% 318/660 |
-8.66% 105/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 民生加银港股通高股息A VS. 长安沪深300非周期A(740101) |